SCHEMBL4265697

SCHEMBL4265697

O=C(O)c1cc(-c2ccccc2)nc(-c2ccccc2)n1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 1/20 0.58
MCL1 Q07820 2/20 0.57
MEN1 O00255 4/20 0.56
KMT2A Q03164 4/20 0.56
NTSR1 P30989 1/20 0.56
ADORA1 P30542 7/20 0.54
ADORA3 P0DMS8 5/20 0.54
ADORA2A P29274 5/20 0.54
ALDH1A1 P00352 4/20 0.53
MAPT P10636 3/20 0.53
HPGD P15428 3/20 0.53
KDM4E B2RXH2 3/20 0.53
NPSR1 Q6W5P4 1/20 0.53
RXFP1 Q9HBX9 1/20 0.53
CYP2C19 P33261 1/20 0.53
CTRC Q99895 1/20 0.51
PTP4A3 O75365 1/20 0.50
ADORA2B P29275 1/20 0.50
LMNA P02545 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2928253 0.86 MCL1 (0.66) MCL1ADORA3ALDH1A1MAPTHPGD
SCHEMBL30937999 0.85 ADORA1 (0.59) MEN1KMT2ANTSR1ADORA1ADORA3
SCHEMBL4829425 0.85 KDM4E (0.60) MEN1KMT2ANTSR1ADORA1ADORA3
SCHEMBL2928227 0.84 ADORA2A (0.50) KMOMCL1ADORA1ADORA3ADORA2A
SCHEMBL2259547 0.84 ADORA3 (0.56) KMOMCL1MEN1KMT2AADORA1
SCHEMBL21001267 0.84 MCL1 (0.61) KMOMCL1MEN1KMT2AADORA3
SCHEMBL981519 0.83 HPGDS (0.46) KMOMCL1MEN1KMT2ANTSR1
SCHEMBL2577413 0.81 LMNA (0.61) MEN1KMT2AADORA1ADORA3ADORA2A
SCHEMBL931017 0.81 ADORA2A (0.66) KMOMCL1MEN1KMT2AADORA1
SCHEMBL523744 0.81 LMNA (0.56) KMOMCL1MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090048258-A1 Amide Compound TAKEDA, PHARMACEUTICAL COMPANY LIMITED (JP) 2009-02-19 US disclosed
US-20090048258-A1 Amide Compound TAKEDA, PHARMACEUTICAL COMPANY LIMITED (JP) 2009-02-19 US disclosed
US-20090048258-A1 Amide Compound TAKEDA, PHARMACEUTICAL COMPANY LIMITED (JP) 2009-02-19 US disclosed
EP-1845081-A1 AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2007-10-17 EP disclosed
EP-1845081-A1 AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048258-A1 Amide Compound DLAT, DGAT1, DGAT2 KMO 3705/4885MCL1 3227/4885MEN1 4668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.